alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 301–325 of 530 studies · free to read (page 13 of 22) · 31,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Showing 530 studies tagged mini-mental — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,851 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Efficacy of cognitive rehabilitation therapies for mild cognitive impairment (MCI) in older adults: working toward a theoretical model and evidence-based interventions

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neuropsychology review 2013-03-08

To evaluate the efficacy of cognitive rehabilitation therapies (CRTs) for mild cognitive impairment (MCI). 4 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

A Single-Channel EEG-Based Approach to Detect Mild Cognitive Impairment via Speech-Evoked Brain Responses

✓ Peer-reviewed alzhub usefulness score 48 out of 100. IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society 2019-04-18

Mild cognitive impairment (MCI) is the preliminary stage of dementia, which may lead to Alzheimer's disease (AD) in the elderly people. 3 key findings →

Participants: 23 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Deep learning-based EEG analysis to classify normal, mild cognitive impairment, and dementia: Algorithms and dataset

✓ Peer-reviewed alzhub usefulness score 48 out of 100. NeuroImage 2023-03-29

For automatic EEG diagnosis, this paper presents a new EEG data set with well-organized clinical annotations called Chung-Ang University Hospital EEG (CAUEEG), which has event history, patient's age, and corresponding diagnosis labels. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Montreal Cognitive Assessment 5-minute protocol is a brief, valid, reliable, and feasible cognitive screen for telephone administration

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Stroke 2015-02-19

The National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization working group proposed a brief cognitive protocol for screening of vascular cognitive impairment. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Accuracy of the Mini-Mental State Examination and Montreal Cognitive Assessment in Detecting Cognitive Impairment in Older Adults: A Comparative Study Adjusted for Educational Level

✓ Peer-reviewed alzhub usefulness score 48 out of 100. NeuroSci 2025-09-05

Early detection of cognitive decline in older adults is essential for implementing timely interventions. 4 key findings →

Design: cross-sectional Participants: 90 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Speech-based digital cognitive assessments for detection of mild cognitive impairment: Validation against paper-based neurocognitive assessment scores

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of Alzheimer s Disease 2025-05-25

Our findings support speech-based cognitive assessments as a promising avenue towards remote MCI screening, with implications for scalable screening in clinical trials and healthcare. 3 key findings →

Participants: 110 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Obfuscation via pitch‐shifting for balancing privacy and diagnostic utility in voice‐based cognitive assessment

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer s & Dementia 2025-03-01

With the top 20 acoustic features, our framework achieved classification accuracies of 62.2% (EER: 0.3335) on the FHS dataset for NC, MCI, and DE differentiation, and 63.7% (EER: 0.1796) on the DBD dataset for NC and MCI differentiation, using obfuscated speech files. 5 key findings →

Participants: 128 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Comparison of Deep Learning and Traditional Machine Learning Models for Predicting Mild Cognitive Impairment Using Plasma Proteomic Biomarkers

✓ Peer-reviewed alzhub usefulness score 48 out of 100. International Journal of Molecular Sciences 2025-03-08

Mild cognitive impairment (MCI) is a clinical condition characterized by a decline in cognitive ability and progression of cognitive impairment. 3 key findings →

Participants: 239 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Prognostic Value of a Multivariate Gut Microbiome Model for Progression from Normal Cognition to Mild Cognitive Impairment Within 4 Years

✓ Peer-reviewed alzhub usefulness score 48 out of 100. International Journal of Molecular Sciences 2025-05-15

Little is known about the dysbiosis of the gut microbiome in patients with mild cognitive impairment (MCI) potentially at risk for the development of Alzheimer's disease (AD). 5 key findings →

Design: cross-sectional Participants: 14 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Time‐dependent biomarker accuracy in forecasting mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer s & Dementia 2025-12-01

Neurophysiological activity features and tau pet provided additional information to the clinical model when acquired up to ∼4 years prior to diagnosis, but their accuracy decreased at larger intervals. 5 key findings →

Design: longitudinal study Participants: 102 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A pilot randomized controlled double-blind trial of intermittent theta burst stimulation (iTBS) repetitive transcranial magnetic stimulation (rTMS) to improve memory in mild cognitive impairment (MCI): a study protocol

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Pilot and Feasibility Studies 2025-04-01

This innovative study aims to test the feasibility of iTBS as a cognitive enhancement strategy in MCI. 3 key findings →

Participants: 20 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Performance of a smell identification test versus the Mini-Mental Status Exam for the detection of dementia and cognitive impairment among persons with cognitive concerns in primary care

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of Alzheimer s Disease 2025-05-21

BackgroundOdor identification deficits predict Alzheimer's disease (AD) in epidemiological studies. 5 key findings →

Design: cross-sectional Participants: 600 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Working memory and executive function decline across normal aging, mild cognitive impairment, and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 47 out of 100. BioMed research international 2015-10-15

Alzheimer's disease (AD) is a progressive neurodegenerative disease marked by deficits in episodic memory, working memory (WM), and executive function. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mild Cognitive Impairment in Clinical Practice: A Review Article

✓ Peer-reviewed alzhub usefulness score 47 out of 100. American journal of Alzheimer's disease and other dementias 2018-08-01

The spectrum of cognitive decline in the elderly ranges from what can be classified as normal cognitive decline with aging to subjective cognitive impairment to mild cognitive impairment (MCI) to dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of neurology 1999-06-01

To determine whether the medial temporal lobe is atrophic in subjects with mild cognitive impairment, and whether atrophy of this structure is a better predictor of dementia than memory dysfunction. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events